Elanco’s Zenrelia granted positive opinion by EU veterinary product committee

Elanco (ELAN) announced that Zenrelia – ilunocitinib – has been granted a positive opinion by the European Medicines Agency’s Committee for Veterinary Medicinal Products, or CVMP, paving the way for the product’s marketing authorization in the European Union in the next 60 days. The CVMP recommended granting the marketing authorization based on the quality, safety and efficacy demonstrated in the data submitted and the favorable benefit-risk balance. Elanco expects to launch the product shortly after receiving marketing authorization with supply in the marketplace before the end of Q3. Zenrelia is already available in Brazil, Canada, Japan and the U.S., and the company expects additional approvals in Australia and the U.K. in 2025.